Biotest Valuation
Is 0N6Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0N6Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0N6Z (€41) is trading below our estimate of fair value (€144.32)
Significantly Below Fair Value: 0N6Z is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0N6Z?
Key metric: As 0N6Z is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0N6Z's PE Ratio? | |
|---|---|
| PE Ratio | 15.9x |
| Earnings | €68.50m |
| Market Cap | €1.37b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.8x |
| Enterprise Value/EBITDA | 19.5x |
| PEG Ratio | 0.5x |
Price to Earnings Ratio vs Peers
How does 0N6Z's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 58.2x | ||
GNS Genus | 142.9x | 37.7% | UK£1.1b |
BVXP Bioventix | 24.2x | n/a | UK£195.7m |
ERGO Ergomed | 46.7x | 14.2% | UK£701.1m |
HIK Hikma Pharmaceuticals | 19x | 12.8% | UK£4.3b |
0N6Z Biotest | 15.9x | 29.3% | €1.4b |
Price-To-Earnings vs Peers: 0N6Z is good value based on its Price-To-Earnings Ratio (15.9x) compared to the peer average (59.7x).
Price to Earnings Ratio vs Industry
How does 0N6Z's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0N6Z is good value based on its Price-To-Earnings Ratio (15.9x) compared to the European Biotechs industry average (26.9x).
Price to Earnings Ratio vs Fair Ratio
What is 0N6Z's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0N6Z's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.90
7D
1.5%
1Y
14.6%
Formycon
€821.0m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€47.10
7D
4.0%
1Y
-23.5%
hVIVO
UK£155.8m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.22
7D
-16.2%
1Y
22.2%